UCB (EBR:UCB) UCB Media Room: Acquisition of own shares

Transparency directive : regulatory news

10/03/2023 20:00

https://mb.cision.com/Public/18595/3732051/94e67c09410f3778_800x800ar.png ** Acquisition of own shares ------------------------------------------------------------ Brussels (Belgium), 10 March 2023 =E2=80=93 20:00 (CET) =E2=80=93 Regulated= information=C2=A0 Acquisition of own shares In accordance with article 8:4 of the Royal Decree of 29 April 2019 executi= ng the Belgian Code on Companies and Associations, UCB SA/NV (=E2=80=9CUCB= =E2=80=9D or the =E2=80=9CCompany) (Euronext Brussels: UCB) hereby disclose= s certain information in relation to its Share Repurchase Program 2023.=C2= =A0 Under this program, UCB has requested a financial intermediary to repurchas= e up to 500 000 UCB shares on its behalf under the terms of a discretionary= mandate agreement with initial validity until 28 April 2023, effective as = from 27 February 2023, to cover current and future obligations under UCB's = Long Term Incentive Plans for its personnel. In the framework of this Share Repurchase Program 2023, UCB repurchased 148= 197 UCB shares on Euronext Brussels in the period from 3 March 2023 up to = and including 9 March 2023, as follows:=C2=A0 https://mb.cision.com/Public/18595/3732051/ad0c81ad0d6b2482_800x800ar.png This press release is available on UCB SA/NV=E2=80=99s website via the foll= owing link (https://www.ucb.com/stories-media/Press-Releases) . For further information, contact UCB:=C2=A0 Investor Relations Antje Witte=C2=A0 T +32 2 559 94 14 antje.witte@ucb.com Corporate Communications Laurent Schots=C2=A0 T+32 2 559 92 64 laurent.schots@ucb.com =C2=A0=C2=A0 =C2=A0 About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company = focused on the discovery and development of innovative medicines and soluti= ons to transform the lives of people living with severe diseases of the imm= une system or of the central nervous system. With approximately 8 700 peopl= e in 36 countries, the company generated revenue of =E2=82=AC 5.5 billion i= n 2022. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twit= ter: @UCB_news GenericFile 230310 - Verwerving van eigen aandelen NL final (https://mb.cision.com/Publ= ic/18595/3732051/85eff61f2d4c9106.pdf) GenericFile 230310 - Acquisition of own shares ENG final (https://mb.cision.com/Public/= 18595/3732051/92ce16fadeab023b.pdf) GenericFile 230310 - Rachat d actions propres FR final (https://mb.cision.com/Public/18= 595/3732051/82a9a314824418fb.pdf) Image Chart 1 March 10 2023 (https://mb.cision.com/Public/18595/3732051/ad0c81ad0= d6b2482_org.png) ______________________ If you would rather not receive future communications from UCB SA, please g= o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x131004x1x6868579x2400= 0x6&Email=3Dregnews%40symexglobal.com. UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium

UCB's latest news

26/04/2024 20:00

UCB (EBR:UCB) UCB Media Room: Acquisition of own shares

Transparency directive : regulatory news

UCB's latest news

Other stories